Aclaris Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Aclaris Therapeutics sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Aclaris Therapeutics: 33 sponsored US clinical trials, 1 recruiting.
Aclaris Therapeutics sponsors 33 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 28 completed. 8 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Common Wart, with 2 trials.
Top-decile sponsor footprint
Aclaris Therapeutics ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
28 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
33 total, page 1 of 1
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06585202
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
NCT05511519
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
NCT05432596
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
NCT05279417
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05216224
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
NCT04524858
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
NCT04598269
Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
NCT04247815
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03812510
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03759340
Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03687372
A Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03691831
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
NCT03585296
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
NCT03594227
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
NCT03551821
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
NCT03495817
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
NCT03487588
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
NCT03468855
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
NCT03315689
Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
NCT03380390
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
NCT03354637
A Phase2 of A-101 Topical Solution in Subjects With Common Warts
NCT03210337
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
NCT03278028
A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
NCT03224598
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
NCT03148691
A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
NCT02667275
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
NCT02667236
An Open-Label Safety Study of A-101 Solution
NCT02667288
A Study of A-101 Solution in Subjects With Common Warts.
NCT02669862
Study of A-101 for the Treatment of Seborrheic Keratosis
NCT02260180
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
NCT02160626
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
NCT01986920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 24 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Aclaris Therapeutics pipeline
1 recruiting of 33 indexed (3% open); 28 completed (85%).
Phase mix: 8 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Common Wart (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Aclaris Therapeutics: open-pipeline peers nationwide
Peers matched on 33 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Aclaris Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 trials (± recruiting share)
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
- Centocor · 33 trials · 0% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Sarepta Therapeutics · 3% recruiting · 33 trials
- National Center for Complementary and Integrative Health (NCCIH) · 3% recruiting · 203 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
Related
What to do with this Aclaris Therapeutics page
33 registered trials is a research-attention snapshot, not an endorsement of Aclaris Therapeutics or any single study.
- 1 of Aclaris Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Common Wart is the condition Aclaris Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Common Wart trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Aclaris Therapeutics pipeline card: 33 registered trials from official public datasets.Report a data error.